Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 8/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17844560 | 0.85 | KMT2A (0.41) | DRD2DRD3P2RX7MEN1KMT2A | |
| SCHEMBL17844489 | 0.84 | P2RX7 (0.46) | P2RX7 | |
| SCHEMBL17844452 | 0.84 | NOS1 (0.41) | NOS1DRD2DRD4DRD3P2RX7 | |
| SCHEMBL17865306 | 0.82 | HDAC4 (0.51) | DRD2DRD3P2RX7 | |
| SCHEMBL19715837 | 0.81 | KMT2A (0.39) | DRD2DRD3P2RX7MEN1KMT2A | |
| SCHEMBL17865267 | 0.81 | KCNH2 (0.40) | DRD2DRD3P2RX7MEN1KMT2A | |
| SCHEMBL17844492 | 0.79 | HDAC4 (0.48) | DRD2DRD4DRD3P2RX7 | |
| SCHEMBL17844460 | 0.78 | DRD2 (0.43) | DRD2DRD4DRD3P2RX7MEN1 | |
| SCHEMBL17844620 | 0.77 | MEN1 (0.50) | DRD2DRD4DRD3MEN1KMT2A | |
| SCHEMBL17844619 | 0.77 | KMT2A (0.50) | DRD2DRD4DRD3P2RX7MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189828-B2 | 1-methylpyrazole-piperazine compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2019-01-29 | — | — | US | claimed |
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-12-21 | — | — | US | claimed |
| US-10189828-B2 | 1-methylpyrazole-piperazine compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2019-01-29 | — | — | US | disclosed |
| US-10189828-B2 | 1-methylpyrazole-piperazine compounds having multimodal activity against pain | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2019-01-29 | — | — | US | disclosed |
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-12-21 | — | — | US | disclosed |
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-12-21 | — | — | US | disclosed |
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-12-21 | — | — | US | disclosed |
| EP-3233830-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096126-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016096126-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362215-A1 | 1-METHYLPYRAZOLE-PIPERAZINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRD1, OPRM1, SIGMAR1 | NOS3 547/4885NOS1 840/4885DRD2 86/4885 |
| US-10189828-B2 | 1-methylpyrazole-piperazine compounds having multimodal activity against pain | OPRD1, OPRM1, SIGMAR1 | NOS3 547/4885NOS1 840/4885DRD2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.